|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
24,270,000 |
Market
Cap: |
519.14(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$20.03 - $40.81 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Fulgent Genetics is a holding company. Through its subsidiaries, Co. is a technology company providing COVID-19 testing services, molecular diagnostic testing services and genetic testing designed to provide physicians and patients with clinically actionable diagnostic information to improve the quality of patient care. Co. has developed a proprietary technology platform allowing Co. to provide a test menu. Combining next generation sequencing with its technology platform, Co. performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels that can be tailored to meet customer needs.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
26,653 |
51,184 |
66,172 |
Total Sell Value |
$0 |
$711,752 |
$1,535,512 |
$2,170,834 |
Total People Sold |
0 |
3 |
3 |
4 |
Total Sell Transactions |
0 |
4 |
16 |
32 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Gao Hanlin |
Chief Scientific Officer |
|
2024-04-26 |
4 |
D |
$20.10 |
$23,195 |
D/D |
(1,154) |
927,811 |
|
- |
|
Xie Jian |
President and COO |
|
2024-04-26 |
4 |
D |
$20.10 |
$87,314 |
D/D |
(4,344) |
363,394 |
|
- |
|
Kim Paul |
CFO and Treasurer |
|
2024-04-26 |
4 |
D |
$20.10 |
$55,034 |
D/D |
(2,738) |
219,672 |
|
- |
|
Kim Paul |
CFO and Treasurer |
|
2024-03-01 |
4 |
D |
$23.24 |
$36,092 |
D/D |
(1,553) |
222,410 |
|
- |
|
Xie Jian |
President and COO |
|
2024-03-01 |
4 |
D |
$23.24 |
$34,372 |
D/D |
(1,479) |
367,738 |
|
- |
|
Gao Hanlin |
Chief Scientific Officer |
|
2024-03-01 |
4 |
D |
$23.24 |
$22,589 |
D/D |
(972) |
928,965 |
|
- |
|
Gao Hanlin |
Chief Scientific Officer |
|
2024-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
30,377 |
929,937 |
|
- |
|
Gao Hanlin |
Chief Scientific Officer |
|
2024-02-26 |
4 |
D |
$24.26 |
$79,815 |
D/D |
(3,290) |
908,791 |
|
- |
|
Kim Paul |
CFO and Treasurer |
|
2024-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
34,862 |
223,963 |
|
- |
|
Kim Paul |
CFO and Treasurer |
|
2024-02-26 |
4 |
D |
$24.26 |
$138,743 |
D/D |
(5,719) |
199,231 |
|
- |
|
Xie Jian |
President and COO |
|
2024-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
35,636 |
369,217 |
|
- |
|
Xie Jian |
President and COO |
|
2024-02-26 |
4 |
D |
$24.26 |
$134,134 |
D/D |
(5,529) |
343,867 |
|
- |
|
Hsieh Ming |
Chief Executive Officer |
|
2024-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
99,721 |
714,373 |
|
- |
|
Hsieh Ming |
Chief Executive Officer |
|
2024-02-26 |
4 |
D |
$24.26 |
$437,893 |
D/D |
(18,050) |
648,421 |
|
- |
|
Hsieh Ming |
Chief Executive Officer |
|
2024-02-23 |
4 |
D |
$24.06 |
$208,528 |
D/D |
(8,667) |
632,702 |
|
- |
|
Gao Hanlin |
Chief Scientific Officer |
|
2024-02-23 |
4 |
D |
$24.06 |
$38,905 |
D/D |
(1,617) |
902,850 |
|
- |
|
Kim Paul |
CFO and Treasurer |
|
2024-02-23 |
4 |
D |
$24.06 |
$64,240 |
D/D |
(2,670) |
194,820 |
|
- |
|
Xie Jian |
President and COO |
|
2024-02-23 |
4 |
D |
$24.06 |
$62,845 |
D/D |
(2,612) |
339,110 |
|
- |
|
Xie Jian |
President and COO |
|
2024-02-03 |
4 |
D |
$24.65 |
$165,623 |
D/D |
(6,719) |
351,722 |
|
- |
|
Kim Paul |
CFO and Treasurer |
|
2024-02-03 |
4 |
D |
$24.65 |
$24,206 |
D/D |
(982) |
197,490 |
|
- |
|
Hsieh Ming |
Chief Executive Officer |
|
2024-02-01 |
4 |
D |
$24.99 |
$27,339 |
D/D |
(1,094) |
641,369 |
|
- |
|
Gao Hanlin |
Chief Scientific Officer |
|
2024-01-30 |
4 |
D |
$25.00 |
$2,250 |
D/D |
(90) |
904,467 |
|
- |
|
Gao Hanlin |
Chief Scientific Officer |
|
2024-01-26 |
4 |
D |
$25.60 |
$33,920 |
D/D |
(1,325) |
904,557 |
|
- |
|
Kim Paul |
CFO and Treasurer |
|
2024-01-26 |
4 |
D |
$25.60 |
$50,893 |
D/D |
(1,988) |
198,472 |
|
- |
|
Xie Jian |
President and COO |
|
2024-01-26 |
4 |
D |
$25.60 |
$119,885 |
D/D |
(4,683) |
358,441 |
|
- |
|
277 Records found
|
|
Page 1 of 12 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|